Heart Rate or Beta-Blocker Dose? Association With Outcomes in Ambulatory Heart Failure Patients With Systolic Dysfunction: Results From the HF-ACTION Trial

Mona Fiuzat, Daniel Wojdyla, Ileana L. Pina, Kirkwood Adams, David Whellan, Christopher M. O'Connor

Research output: Contribution to journalArticle

35 Scopus citations

Abstract

Objectives: This study aimed to compare whether reduced heart rate (HR) or higher beta-blocker (BB) dose affected outcomes to a greater extent in the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) trial population. Background: Recent data have shown that HR is an important modifiable factor in reducing mortality in heart failure (HF) patients. It has also been shown that titration of doses of BBs improves outcomes of morbidity and mortality in chronic HF patients with reduced ejection fraction. We aimed to compare whether reduced HR or higher BB dose affected outcomes to a greater extent in the HF-ACTION trial population. Methods: HF-ACTION was a randomized, multicenter trial enrolling 2,331 ambulatory HF patients with systolic dysfunction (New York Heart Association functional class II to IV, left ventricular ejection fraction

Original languageEnglish (US)
Pages (from-to)109-115
Number of pages7
JournalJACC: Heart Failure
Volume4
Issue number2
DOIs
StatePublished - Feb 1 2016

Keywords

  • Beta-blockers
  • Dose
  • Exercise
  • Heart failure
  • Heart rate
  • Mortality

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Heart Rate or Beta-Blocker Dose? Association With Outcomes in Ambulatory Heart Failure Patients With Systolic Dysfunction: Results From the HF-ACTION Trial'. Together they form a unique fingerprint.

  • Cite this